Hôpital Louis

1 month ago | onlinelibrary.wiley.com | François Meyer |Hôpital Louis |Juliette Cotte |Lucas Bento

1 Introduction For nearly 40 years, the artificial urinary sphincter (AUS) has been the gold standard treatment in male patients with mild or severe stress urinary incontinence (SUI). The AMS 800 AUS (Boston Scientific, Marlborough, Massachusetts, MA, USA) is the most widely used device for the treatment of moderate to severe SUI in men, with no major recent modification of the device itself. Most studies are retrospective, but large cohorts have been published [1-3].

2 months ago | academic.oup.com | Foster City |Hôpital Louis

Lenacapavir is a highly potent first-in-class inhibitor of HIV-1 capsid approved for the treatment of heavily treatment-experienced (HTE) people with HIV-1 (PWH) harboring multidrug resistant (MDR) virus, in combination with an optimized background regimen (OBR). Resistance analyses conducted after 2 years of lenacapavir treatment in the phase 2/3 CAPELLA study are described. CAPELLA enrolled viremic HTE PWH with resistance to 2 or more drugs per class in at least 3 of the 4 main drug classes.

May 13, 2023 | ashpublications.org | New York-Presbyterian |Hôpital Saint-Antoine |Hôpital Louis |Wessex Blood

In this registry-based analysis of patients undergoing allogeneic HSCT, we found that individual comorbidities vary widely in their clinical significance for NRM in the low-TCI setting. Intensity selection is strongly linked to comorbidity burden.7 However, the prognostic importance of individual comorbidities among patients selected as requiring the lowest intensity conditioning remains poorly understood.